Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for adhd
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:
hyperactivity and impulsiveness
Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).
Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).
Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.
Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).
; firstname.lastname@example.org. eng Journal Article Comment 2015 10 01 England Evid Based Ment Health 100883413 1362-0347 IM J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):263-74 25791143 AttentionDeficitDisorder with Hyperactivity Humans Referral and Consultation Telemedicine PUBLIC HEALTH 2015 06 22 2015 09 15 2015 10 3 6 0 2015 10 3 6 0 2016 8 25 6 0 ppublish 26429338 eb-2015-102151 10.1136/eb-2015-102151 (...) Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. 26429338 2016 08 24 2018 12 02 1468-960X 18 4 2015 Nov Evidence-based mental health Evid Based Ment Health Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. e9 10.1136/eb-2015-102151 Rockhill Carol C Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivitydisorder (ADHD): nationwide self controlled case series study. To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivitydisorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged (...) in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly
Treatment of Attention-Deficit/HyperactivityDisorder in Adolescents: A Systematic Review. Although attention-deficit/hyperactivitydisorder (ADHD) is highly prevalent in adolescents and often persists into adulthood, most studies about treatment were performed in children. Less is known about ADHD treatment in adolescents.To review the evidence for pharmacological and psychosocial treatment of ADHD in adolescents.The databases of CINAHL Plus, MEDLINE, PsycINFO, ERIC, and the Cochrane Database (...) Scale (score range, 0 [least symptomatic] to 54 [most symptomatic]), both stimulant and nonstimulant medications led to clinically significant reductions of 14.93 to 24.60 absolute points. The psychosocial treatments combining behavioral, cognitive behavioral, and skills training techniques demonstrated small- to medium-sized improvements (range for mean SD difference in Cohen d, 0.30-0.69) for parent-rated ADHD symptoms, co-occurring emotional or behavioral symptoms, and interpersonal functioning
in March 2016. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Guanfacine prolonged-release (Intuniv) is a non-stimulant treatment for children and young people with attentiondeficithyperactivitydisorder (ADHD). In 3 short-term, randomised controlled trials (RCTs) it was more effective than placebo at improving ADHD symptoms, although a beneficial effect on social functioning (...) February 2016). Atomoxetine 4 mg/ml oral solution (Strattera) costs £23.33–£233.33 for 28 days treatment at a dose of 10–100 mg daily (excluding VAT; Drug T ariff, February 2016). Introduction and current guidance Attentiondeficithyperactivitydisorder (ADHD) is a heterogeneous behavioural syndrome characterised by the core symptoms of hyperactivity, impulsivity and inattention. The NICE guideline on ADHD (currently being updated, publication expected January 2018) covers diagnosing and managing ADHD
: A Review of the Clinical Effectiveness, Safety, and Guidelines Published on: March 3, 2016 Project Number: RC0754-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the effectiveness and safety of high dose stimulants in children and adolescents (six to 18 years) with attention-deficit/hyperactivitydisorder (ADHD)? What is the comparative effectiveness and safety of high dose stimulants in adults (> 18 years) with ADHD? What (...) in adolescents with ADHD was identified; high doses of study medication were more effective than placebo at addressing symptoms, but had uncertain effects on quality of life measures. Three non-randomized studies regarding adverse events for adolescents and adults using high doses of methylphenidate were identified; these doses were generally well tolerated by patients. Tags amphetamine, amphetamines, attentiondeficitdisorder with hyperactivity, central nervous system stimulants, dexamfetamine, dexedrine
patients with ADHD. Tags amphetamine, attentiondeficitdisorder with hyperactivity, delayed-action preparations, dexamfetamine, dexedrine, dexmethylphenidate, dextroamphetamine, focalin, learning disorders, methylphenidate, ritalin, learning disorder, AD/HD, ADD, Adderall, Attentiondeficit, Concerta, Long acting, Slow acting, atomoxetine, controlled delivery, controlled release, delayed release, extended release, immediate release, lisdexamfetamine dimesylate, short acting, sustained release, vyvanse (...) Combination Therapy for AttentionDeficitHyperactivityDisorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/HyperactivityDisorder: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Combination Therapy for Attention-Deficit/HyperactivityDisorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/HyperactivityDisorder: A Review of the Clinical Effectiveness Published on: February 23, 2016
The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study The landmark US Multimodal Treatment of ADHD (MTA) study established the benefits of individualised medication titration and optimisation strategies to improve short- to medium-term outcomes in attention-deficithyperactivitydisorder (ADHD). This individualised medication management approach was subsequently incorporated into the National (...) Institute for Health and Care Excellence (NICE) ADHD Clinical Guidelines (NICE CG78). However, little is known about clinicians' attitudes towards implementing these medication management strategies for ADHD in routine care.To examine National Health Service (NHS) healthcare professionals' consensus on ADHD medication management strategies.Using the Delphi method, we examined perceptions on the importance and feasibility of implementing 103 ADHD treatment statements from sources including the UK NICE
Psychoeducation for adults with AttentionDeficitHyperactivityDisorder (ADHD) Psychoeducation for adults with AttentionDeficitHyperactivityDisorder (ADHD) - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Psychoeducation for adults with AttentionDeficitHyperactivityDisorder (ADHD (...) ) Have you found an error? Order Download: Key message The Norwegian Institute of Public Health, Knowledge Centre was commissioned by “Bestillerforum RHF” to undertake a rapid review of research on Psychoeducation for adults with AttentionDeficitHyperactivityDisorder (ADHD). Methods We conducted a systematic search in nine medical, social science and health-related databases to identify relevant research publications about adults with ADHD and psychoeducative treatment. The search was conducted
of Attention-Deficit/HyperactivityDisorder in Children and Adolescents was developed by the American Academy of Pediatrics (AAP) and endorsed by the American Academy of Family Physicians (AAFP). Key Recommendations Any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity should be evaluated for ADHD. The diagnosis of ADHD should be based on the criteria from the Diagnostic and Statistical Manual of Mental Disorders (...) medications for ADHD and may be treated with behavioral therapy. Medication doses should be titrated to achieve maximum benefit with minimum adverse effects. Access the article with full recommendation for more information on ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/HyperactivityDisorder in Children and Adolescents. * Please note that the AAP has also developed a Process of Care Supplemental Appendix document, available on the AAP website, which
. Kernberg OF , Yeomans FE . Borderline personality disorder, bipolar disorder, depression, attentiondeficit/hyperactivitydisorder, and narcissistic personality disorder: practical differential diagnosis . 16. Connor DF , Doerfler LA . ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptivebehaviordisorders? 17. American Academy of Pediatrics . Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity (...) .), University of California at Los Angeles. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis David Gloss , Jay K. Varma , Tamara Pringsheim , Marc R. Nuwer Neurology Nov 2016, 87 (22) 2375-2379; DOI: 10.1212/WNL.0000000000003265 Citation Manager Formats Make Comment See Comments Downloads 2753 Share Abstract Objective: To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivitydisorder (ADHD). Methods: We
Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with AttentionDeficitHyperactivityDisorder Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with AttentionDeficitHyperactivityDisorder | CADTH.ca Find the information you need Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with AttentionDeficitHyperactivityDisorder Duration of Dosage Effect for Methylphenidate SR (...) and Dextroamphetamine SR for Patients with AttentionDeficitHyperactivityDisorder Published on: September 2, 2015 Project Number: RB0904-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence for the duration of dosage effect for methylphenidate SR and dextroamphetamine SR for patients with attentiondeficithyperactivitydisorder? Key Message One systematic review, two randomized controlled trials, and two non-randomized studies were
Non-pharmacological interventions for attention-deficit/hyperactivitydisorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Non-pharmacological interventions for attention-deficit/hyperactivitydisorder (ADHD)delivered in school settings: systematic reviews of quantitative and qualitative research Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page
Medical augmentation of labor and the risk of ADHD in offspring: a population-based study Oxytocin for labor augmentation is widely used in obstetric care in Western countries. Two recent, smaller studies found opposing results regarding the association between prenatal exposure to oxytocin for labor augmentation and attention-deficit/hyperactivitydisorder (ADHD). In Denmark, oxytocin is the medication used for nearly all medical augmentations of labor, and we examined the association between (...) medical augmentation of labor and ADHD in a large cohort study based on national register data.All singletons born after spontaneous onset of labor in Denmark between 2000 and 2008 (N = 546 146) were included in the study. Data from the Danish Medical Birth Registry on medical augmentation of labor (yes/no) were used to identify exposed children. ADHD was defined based on the diagnostic codes of International Classification of Diseases, 10th Revision, for hyperkinetic disorder and information
Mortality in children, adolescents, and adults with attentiondeficithyperactivitydisorder: a nationwide cohort study. Attentiondeficithyperactivitydisorder (ADHD) is a common mental disorder associated with factors that are likely to increase mortality, such as oppositional defiant disorder or conduct disorder, criminality, accidents, and substance misuse. However, whether ADHD itself is associated with increased mortality remains unknown. We aimed to assess ADHD-related mortality (...) in a large cohort of Danish individuals.By use of the Danish national registers, we followed up 1·92 million individuals, including 32,061 with ADHD, from their first birthday through to 2013. We estimated mortality rate ratios (MRRs), adjusted for calendar year, age, sex, family history of psychiatric disorders, maternal and paternal age, and parental educational and employment status, by Poisson regression, to compare individuals with and without ADHD.During follow-up (24·9 million person-years), 5580